Download PDF
Thromb Haemost 2012; 107(01): 189-191
DOI: 10.1160/TH11-05-0306
Letters to the Editor
Schattauer GmbH

The relevance of P2Y12-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: A clinical follow-up

Heleen J. Bouman
1   St Antonius Center for Platelet Function Research, St Antonius Hospital, Nieuwegein, the Netherlands
2   Department of Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands
3   Department of Internal Medicine, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, the Netherlands
5   Department of Clinical Chemistry, St Antonius Hospital, Nieuwegein, the Netherlands
,
Jochem W. van Werkum
1   St Antonius Center for Platelet Function Research, St Antonius Hospital, Nieuwegein, the Netherlands
2   Department of Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands
3   Department of Internal Medicine, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, the Netherlands
,
Goran Rudež
4   Department of Hematology, Erasmus Medical University Center, Rotterdam, the Netherlands
,
Christian M. Hackeng
1   St Antonius Center for Platelet Function Research, St Antonius Hospital, Nieuwegein, the Netherlands
5   Department of Clinical Chemistry, St Antonius Hospital, Nieuwegein, the Netherlands
,
Frank W. G. Leebeek
4   Department of Hematology, Erasmus Medical University Center, Rotterdam, the Netherlands
,
Hugo ten Cate
3   Department of Internal Medicine, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, the Netherlands
,
Jurriën M. ten Berg
1   St Antonius Center for Platelet Function Research, St Antonius Hospital, Nieuwegein, the Netherlands
2   Department of Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands
,
Moniek P. M. de Maat
4   Department of Hematology, Erasmus Medical University Center, Rotterdam, the Netherlands
› Author Affiliations
Further Information

Publication History

Received: 05 May 2011

Accepted after major revision: 14 October 2011

Publication Date:
20 November 2017 (online)

    Permissions and Reprints

 

  • References

  • 1 Fontana P, Dupont A, Gandrille S. et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989-995.
    CrossrefPubMedGoogle Scholar
  • 2 Rudez G, Bouman HJ, van Werkum JW. et al. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. Circ Cardiovasc Genet 2009; 02: 515-521.
    CrossrefPubMedGoogle Scholar
  • 3 Bouman HJ, van Werkum JW, Rudez G. et al. The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor. Thromb Haemost 2010; 103: 379-386.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Breet NJ, van Werkum JW, Bouman HJ. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762.
    CrossrefPubMedGoogle Scholar
  • 5 TIMI Study Group.. Definitions used in TIMI-trials. Available at: http://www.timi.org/wp-content/uploads/2010/10/TIMI-Definitions.pdf Accessed April 12th 2011.
    PubMedGoogle Scholar
  • 6 Cutlip DE, Windecker S, Mehran R. et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351.
    CrossrefPubMedGoogle Scholar
  • 7 Harmsze AM, Robijns K, van Werkum JW. et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010; 103: 920-925.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Sarafoff N, Neumann L, Morath T. et al. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Am Heart J 2011; 161: 605-610.
    CrossrefPubMedGoogle Scholar
  • 9 Bates ER, Lau WC, Angiolillo DJ.. Clopidogrel-drug interactions. J Am Coll Cardiol 2011; 57: 1251-1263.
    CrossrefPubMedGoogle Scholar
  • 10 Patrono C.. The P2Y12 receptor: no active metabolite, no party. Nat Rev Cardiol 2009; 06: 271-272.
    CrossrefPubMedGoogle Scholar
  • 11 Shuldiner AR, O'Connell JR, Bliden KP. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J Am Med Assoc 2009; 302: 849-857.
    CrossrefPubMedGoogle Scholar
  • 12 Bouman HJ, Schomig E, van Werkum JW. et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17: 110-116.
    CrossrefPubMedGoogle Scholar
  • 13 Mega JL, Close SL, Wiviott SD. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
    CrossrefPubMedGoogle Scholar
  • 14 Gurbel PA, Kereiakes DJ, Tantry US.. Ticagrelor for the treatment of arterial thrombosis. Expert Opin Pharmacother 2010; 11: 2251-2259.
    CrossrefPubMedGoogle Scholar
  • 15 Jakubowski JA, Winters KJ, Naganuma H. et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25: 357-374.
    CrossrefPubMedGoogle Scholar